TRIPLECON
Triple negative breast cancer control through synergistic inhibition of EGFR and CDK9 signaling
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0TRIPLECON project word cloud
Explore the words cloud of the TRIPLECON project. It provides you a very rough idea of what is the project "TRIPLECON" about.
Project "TRIPLECON" data sheet
The following table provides information about the project.
| Coordinator |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 150˙000 € |
| EC max contribution | 150˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2017-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-10-01 to 2018-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | NL (ROTTERDAM) | coordinator | 90˙075.00 |
| 2 | UNIVERSITEIT LEIDEN | NL (LEIDEN) | participant | 59˙925.00 |
Map
Project objective
'Triple negative breast cancer (TNBC) is an aggressive disease, accounting for 15-20% of breast cancer cases, but disproportionally causing breast cancer-related death. TNBC does not express the targetable receptors ER, PR, and HER2 that are known to drive other forms of breast cancer. Mainstay practice for TNBC in the clinic is to treat with non-targeted cytotoxic chemotherapies. Long-term outcomes are however still poor, most likely owing to intrinsic drug resistance. Clinical trials have attempted to explore molecular targeted therapies to block dysregulated growth factor receptors in TNBC, for instance, epidermal growth factor receptor (EGFR), as it is overexpressed in ~80% of TNBC. Yet, giving the long-standing availability of clinically approved EGFR-targeted therapies, such as lapatinib, the clinical benefit of single agent therapy is unsatisfactory, owing to the compensatory dysregulated signaling pathways. In our ongoing ERC – Advanced Grant Triple-BC (#322737) we are striving to explore combinatorial molecular targeted therapies to concomitantly block the identified dysregulated signaling pathways. Our preliminary work revealed that an inhibitor targeting cyclin-dependent kinase 9 (CDK9) strikingly synergized with targeting EGFR receptor family signaling to inhibit cell proliferation of TNBC cell lines. The overall goal of this PoC project is to exploit this novel finding and provide proof-of-concept evidence that stalling CDK9 signaling may enable successful targeted combination therapy in TNBC. Therefore, the specific objective is to assess the pharmacological response of dual EGFR-CDK9 targeting in TNBC patient-derived xenograft (PDX) mouse models in vivo. We envisage that this PoC project will translate our identified successful synergistic treatment into an effective future novel and safe combinatorial targeting strategy benefiting TNBC patients.'
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRIPLECON" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRIPLECON" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.1.1.)
NEUTRAMENTH (2018)
A redox-neutral process for the cost-efficient and environmentally friendly production of Menthol
Read More